

Quarterly Formulary Changes Announced (Third Quarter 2026)

Quarterly changes to the Independent Health Drug formularies are summarized below and are currently in effect unless otherwise noted.

NPG/NPB - Non-Preferred Generic/Brand
 PG/PB - Preferred Generic/Brand
 NF - Non-Formulary
 SP - Specialty Pharmacy
 PA - Prior Authorization
 ST – Step Therapy

QL – quantity Limits
 SC – subcutaneous
 IM – intramuscular
 inj – injection
 tab – tablet
 cap – capsule
 oph- ophthalmic

soln – solution
 susp – suspension
 MDI-metered-dose inhalation aerosol
 ODT – orally-disintegrating tablet
 LA-available only at certain pharmacies
 G- Generic (T2) for Medicare

Changes to Drug Formulary I (DF1), FEHB Formulary, and Pharmacy Benefit Dimensions Formulary		
Medications Added to Formulary 10/1/2026	Medications Non-Formulary 10/1/2026	Changes to Formulary 1/1/2027
Avtozma SQ - PB PA (7/1/2026) Starjemza SQ- PB PA (7/1/2026) Pregnyl IM- PG PA (7/1/2026) Lipfendra tabs- NPB, PA w/ ST Utebzi tabs- NPB, PA exc ID Xocova tabs- NPB, AL, QL Jideytro tabs- NPB, PA Zenbexus caps- NPB, PA	Baxfendy tabs- w/ PA Orzeyful tabs- TBD Simtriyo XR cap- w/ PA Trimbrow inh soln Hepcludex SC- w/ PA Trutakna SQ- w/ PA	Vyndamax caps- T3 PA to NF Opsynvi tabs- T3 PA to NF chorionic gonadotropin IM- T1 PA to NF Actemra SQ- T2 PA to NF Yesintek SQ- T2 PA to NF cycloserine tabs- T3 to NF Bethkis nebs- T3 PA to NF Kitabis nebs- T3 PA to NF Azelex cream- T3 to NF cephalixin 750mg caps- T3 to NF nitazoxanide tabs- T1 PA to T3 PA pyrimethamine tabs- T1 PA to T3 PA abiraterone tabs- remove PA (6/3/2026) Ferriprox tabs- T3 PA to NF (6/3/2026) Milnacipran tabs- T3 to T2 (7/2/2026) Savella tabs- T2 to NF (10/1/2026)

Changes to Drug Formulary II (DF2), Drug Formulary III (DF3), and Essential Plan Formulary (EPF)		
Medications Added to Formulary 10/1/2026	Medications Non-Formulary 10/1/2026	Changes to Formulary 1/1/2027
Avtozma SQ - PB PA (7/1/2026) Starjemza SQ- PB PA (7/1/2026) Pregnyl IM- PG PA (7/1/2026) Lipfendra tabs- NPB, PA w/ ST Utebzi tabs- NPB, PA exc ID Xocova tabs- NPB, AL, QL Jideytro tabs- NPB, PA Zenbexus caps- NPB, PA	Baxfendy tabs- w/ PA Orzeyful tabs- TBD Simtriyo XR cap- w/ PA Trimbrow inh soln Hepcludex SC- w/ PA Trutakna SQ- w/ PA	Vyndamax caps- T3 PA to NF Opsynvi tabs- T3 PA to NF chorionic gonadotropin IM- T1 PA to NF Actemra SQ- T2 PA to NF Yesintek SQ- T2 PA to NF cycloserine tabs- T2 to NF Bethkis nebs- T3 PA to NF Kitabis nebs- T3 PA to NF Azelex cream- T3 to NF cephalixin 750mg caps- T3 to NF nitazoxanide tabs- T2 PA to T3 PA pyrimethamine tabs- T2 PA to T3 PA abiraterone tabs- remove PA (6/3/2026) Ferriprox tabs- T3 PA to NF (6/3/2026) Milnacipran tabs- T3 to T2 (7/2/2026) Savella tabs- T2 to NF (10/1/2026)

Changes to Child Health Plus Formulary		
Medications Added to Formulary 10/1/2026	Medications Non-Formulary 10/1/2026	Changes to Formulary 10/1/2026
Xocova tabs- PB, AL, QL	Baxfendy tabs Lipfendra tabs Orzeyful tabs- TBD Simtriyo XR cap Trimbrow inh soln Hepcludex SC Utebzi tabs Trutakna SQ Jideytro tabs Zenbexus caps	

Changes to Medicare Formulary		
Medications Added to Formulary 10/1/2026	Medications Non-Formulary /1/2026	Changes to Formulary /1/2026
Lipfendra tabs- PB PA Utebzi tabs- NPB, PA exc ID Xocova tabs- NPB, AL, QL Jideytro tabs- NPB, PA Zenbexus caps- NPB, PA	Baxfendy tabs Orzeyful tabs- TBD Simtriyo XR cap Trimbrow inh soln Hepcludex SC Trutakna SQ	

Medical with PA: (effective 10/1/2026)

1. Tudriqev (vusolimogene oderparepvec-wtpg) intratumor injection
2. Revtorpyk (gedatolisib) IV injection
3. Decnupaz (pivekimab sunirine-pvzy) IV injection
4. Tregzi (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) IV injection
5. Lumvoa (veligrotug-vvze) IV injection
6. mFlusiva (influenza vaccine, mRNA) intramuscular injection w/ AL (50+)
7. Zaynich (cefepime-zidebactam) IV injection
8. Lytenava (bevacizumab-vikg) intravitreal injection

Expedited reviews:

Brand name	Generic name	Indication(s)	Coverage
Qlonilik	clonidine oral solution	lower blood pressure in adults with hypertension	NF
Gwyn Lo	norelgestromin/ethinyl estradiol transdermal system	a contraceptive indicated for the prevention of pregnancy in women with a BMI <30 kg/m ² for whom a combined hormonal contraceptive (CHC) is appropriate	NF
Sarclisa Escena	isatuximab-irfc SC injection	Multiple myeloma- three exact same indications as IV Sarclisa	Medical, PA
Navitrox	fosaprepitant IV injection	Prevention of acute and delayed nausea and vomiting associated with chemotherapy	Medical, PA w/ ST
Tiocrin	tiopronin tablets	prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria	NF
Cavhanza	nilotinib orally-disintegrating tablets	adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia	NF

Policy updates of drugs with new indications:

Brand name	Generic name	New indication(s)	Coverage changes
Afrezza	insulin human (inhaled)	lower AL down to 6 years of age	PA policy changes
Capvaxive	pneumococcal 21-valent vaccine	2-17 years of age at increased risk of pneumococcal dx	AL changes
Casgev	exagamglogene autotemcel	lower AL down to 2 years of age	PA policy changes
Datroway	datopotamab deruxtecan-dlnk	triple negative breast Ca if PD-1/PD-L1 ineligible	Prime policy update
Hypavzi	marstacimab-hncq	hemophilia A or B in patients 12+ w/inhibitors	Prime policy update
Hypavzi	marstacimab-hncq	hemophilia A or B w/o inhibitors down to 6 y.o.	Prime policy update
Ibrance	palbociclib	part of 1 st -line regimen for HR+/HER2+ breast Ca	Prime policy update
Imfinzi	durvalumab	w/BCG, BCG-naïve high-risk NMIBC	Prime policy update
Keytruda/Qlex	pembrolizumab	w/Padcev muscle invasive bladder cancer	Prime policy update
Linze	linaclotide	functional constipation down to 2 years of age	AL changes
Padcev	enfortumab vedotin-ejfv	w/Keytruda muscle invasive bladder cancer	Prime policy update
Pluvicto	Lu-177 vipivotide tetraxetan	PSMA+ metastatic mAPMN/S prostate cancer	UM policy update
Rezzayo	rezafungin	lower AL down to 12 years of age	PA policy changes
Ryaltris	olopatadine/mometasone	lower AL down to 6 years of age	n/a
Skyrzi	risankizumab-rzaa	PsA down to 6 years of age	PA policy changes
Skyrzi	risankizumab-rzaa	PsO down to 6 years of age	PA policy changes
Trodelvy	sacituzumab govitecan-hziy	newly-diagnosed patients w/triple negative breast Ca	Prime policy update
Truqap	capiasertib	PTEN(-) mAPMN/S prostate cancer w/abiraterone	PA policy changes
Tryngolza	olezarsen	severe hypertriglyceridemia	remove ST
Tzield	teplizumab-mzwv	delay decline in insulin production in patients 8-17 years recently diagnosed with Stage 3 T1D	PA policy changes
Upravi	selexipag	lower AL down to 2 years of age	PA policy changes
Welireg	belzutifan	RCC w/clear cell component w/pembrolizumab	PA policy changes
wilate	vWF/factor VIII complex	vWD prophylaxis lower AL eliminated	Prime policy update
Xeomin	incobotulinumtoxinA	upper limb spasticity caused by cerebral palsy in peds	n/a
Zegalogue	dasiglucagon	can now be used in patients ≥20 kg	n/a
Zoryve	roflumilast 0.3% cream	PsA down to 2 years of age	n/a

New generics:

Brands now non-formulary unless otherwise indicated. For Medicaid, medical drugs will be covered as Commercial unless otherwise specified below.

Brand name	Generic name	Generic tier placement and utilization management			
		Commercial/ FEHB	Exch/Small/EBP	Medicaid	Medicare Indiv/PDP
Bosulif	bosutinib	NPG, PA	NPG, PA	NF	T5 PA/T1 PA
Cotempla XR	<i>authorized generic only</i>	NF	NF	NF	NF/NF
Injectafer	ferric carboxymaltose	Medical	Medical	Medical	Medical
Janumet	sitagliptin/metformin	NF	NF	NF	NF/NF
Januvia	sitagliptin	NF	NF	NF	T3/T1
Myrbetriq	mirabegron oral suspension	T1	T1	NF	NF/NF
Nuedexta	dextromethorphan/quinidine	T1 PA	T1 PA	NF	T5 PA/T1 PA
Opsumit	macitentan	T2 PA/T4 PA	T2 PA	T1 PA	T5 PA/T1 PA
Pentasa	mesalamine CR 250 mg caps	T1	T1	T1	NF/T1
Priftin	rifapentine	T3	T3	NF	T4/T1
Rhofade	oxymetazoline cream	NF	NF	NF	NF/NF
Syndros	<i>authorized generic only</i>	NF	NF	NF	NF/NF
Tigan	trimethobenzamide injectable	Medical	Medical	Medical	Medical/Medical
Xeljanz/XR	tofacitinib	T1 PA	T1 PA	NF	T3 & T5/T1

Biosimilar drug changes:

Biosimilar (generic name)	Reference Product	Changes	Effective date
Garzulys (insulin aspart- fsan)	Novolog	NF	10/1/2026
Ranluspec (ranibizumab-hkdz)	Lucentis	Medical, PA w/ ST	10/1/2026
Immgolis/ Immgis Intri (golimumab-sldi)	Simponi/ Simponi Aria	TBD- based on cost	10/1/2026
Ennumo (pegfilgrastim- pccg)	Neulasta	Medical, PA w/ ST	10/1/2026

Products removed from market

1. Vizimpro (dacomitinib)- removed on 6/8/2026